MoonLake Immunotherapeutics
For the period ended Jun 30, 2024. Filed Aug 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 7, 2024
MLTX$12.56-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses | ||||
| Research and development | $(23,662,147) | $(8,703,849) | $(36,676,194) | $(16,118,949) |
| General and administrative | (6,916,054) | (4,482,041) | (13,722,500) | (9,998,510) |
| Total operating expenses | (30,578,201) | (13,185,890) | (50,398,694) | (26,117,459) |
| Operating loss | (30,578,201) | (13,185,890) | (50,398,694) | (26,117,459) |
| Other income, net | 5,898,148 | 842,652 | 11,813,372 | 1,566,242 |
| Loss before income tax | (24,680,053) | (12,343,238) | (38,585,322) | (24,551,217) |
| Income tax expense | (78,701) | (10,149) | (148,953) | (21,157) |
| Net loss | $(24,758,754) | $(12,353,387) | $(38,734,275) | $(24,572,374) |
| Of which: net loss attributable to controlling interests shareholders | (24,267,012) | (10,139,279) | (37,940,668) | (19,144,135) |
| Of which: net loss attributable to noncontrolling interests shareholders | (491,742) | (2,214,108) | (793,607) | (5,428,239) |
| Net unrealized gain (loss) on marketable securities and short term investments | 652,097 | (415,225) | 834,370 | (390,753) |
| Actuarial gain (loss) on employee benefit plans | (76,479) | (16,336) | 4,751 | (58,481) |
| Other comprehensive income (loss) | 575,618 | (431,561) | 839,121 | (449,234) |
| Comprehensive loss | $(24,183,136) | $(12,784,948) | $(37,895,154) | $(25,021,608) |
| Comprehensive loss attributable to controlling interests shareholders | (23,703,201) | (10,488,185) | (37,118,908) | (19,505,667) |
| Comprehensive loss attributable to noncontrolling interests | (479,935) | (2,296,763) | (776,246) | (5,515,941) |
| Weighted-average number of Class A Ordinary Shares, basic and diluted | 62,874,637 | 43,718,464 | 62,755,925 | 41,403,084 |
| Basic and diluted net loss per share attributable to controlling interests shareholders | $(0.39) | $(0.23) | $(0.60) | $(0.46) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.